RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Vakaramoko Diaby to Humans

Back to Details
This is a "connection" page, showing publications Vakaramoko Diaby has written about Humans.
Vakaramoko Diaby
Connection Strength
1.445
Humans
  1. Sanogo V, Saud Almutairi RD, Diaby V. Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis. Expert Rev Pharmacoecon Outcomes Res. 2025 Dec; 25(10):1421-1426.
    View in: PubMed
    Score: 0.042
  2. Diaby V, Pandey S, Sanogo V, Dhayan Almutairi R, Kanoria Y, Nag SS. Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States. J Manag Care Spec Pharm. 2025 Jan; 31(1):53-59.
    View in: PubMed
    Score: 0.041
  3. Diaby V, Pandey S, Sanogo V, Almutairi RD, Kanoria Y, Nag SS. Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States. J Manag Care Spec Pharm. 2025 Jan; 31(1):60-67.
    View in: PubMed
    Score: 0.041
  4. Berthe A, Eljilany I, Kulkarni A, Diaby V. A bibliometric analysis and typology of drug pricing policies across the globe. Medicine (Baltimore). 2024 Oct 18; 103(42):e40112.
    View in: PubMed
    Score: 0.040
  5. Ali AA, Kulkarni A, Bhattacharjee S, Diaby V. Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework. Pharmacoeconomics. 2024 Jul; 42(Suppl 2):211-224.
    View in: PubMed
    Score: 0.039
  6. Nkemdirim Okere A, Moussa RK, Ali A, Diaby VK. Development and validation of a tool to predict high-need, high-cost patients hospitalised with ischaemic heart disease. BMJ Open. 2023 09 26; 13(9):e073485.
    View in: PubMed
    Score: 0.038
  7. Sanogo V, Chen Z, Almutairi RD, Hong X, Diaby V. Predictors of 30-day readmission, mortality, and length of stay for hospitalized U.S. patients with Alzheimer's and related dementias from 2010 to 2015. Expert Rev Pharmacoecon Outcomes Res. 2023 Jun; 23(5):555-559.
    View in: PubMed
    Score: 0.036
  8. Tran PT, Riaz M, Chen Z, Truong CB, Diaby V. An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines. Clin Drug Investig. 2022 May; 42(5):377-390.
    View in: PubMed
    Score: 0.034
  9. Diaby V, Babcock A, Huang Y, Moussa RK, Espinal PS, Janvier M, Soler D, Gupta A, Jayakar P, Diaz-Barbosa M, Totapally B, Sasaki J, Jayakar A, Salyakina D. Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States. Pharmacogenomics J. 2022 07; 22(4):223-229.
    View in: PubMed
    Score: 0.034
  10. Ali AA, Tawk R, Xiao H, Semykina A, Montero AJ, Moussa RK, Popoola O, Diaby V. Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2022 Jul; 22(5):735-741.
    View in: PubMed
    Score: 0.034
  11. Diaby V, Ali A, Babcock A, Fuhr J, Braithwaite D. Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions. J Manag Care Spec Pharm. 2021 Sep; 27(9-a Suppl):S22-S29.
    View in: PubMed
    Score: 0.033
  12. Chen Z, Babcock A, Sanogo V, Nelson DR, Xiao H, Diaby V. Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr; 22(3):409-415.
    View in: PubMed
    Score: 0.032
  13. Babcock A, Moussa RK, Diaby V. Effects, trends, costs associated with readmission in early-aged patients with suicidal ideation. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar; 22(2):247-258.
    View in: PubMed
    Score: 0.032
  14. Chen Z, Cheng Y, DeRemer D, Diaby V. Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct; 21(5):923-941.
    View in: PubMed
    Score: 0.032
  15. Diaby V, Almutairi RD, Chen Z, Moussa RK, Berthe A. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19. Expert Rev Pharmacoecon Outcomes Res. 2021 Feb; 21(1):159-168.
    View in: PubMed
    Score: 0.031
  16. Diaby V, Almutairi RD, Babcock A, Moussa RK, Ali A. Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun; 21(3):353-364.
    View in: PubMed
    Score: 0.031
  17. Okere AN, Sanogo V, Alqhtani H, Diaby V. Identification of risk factors of 30-day readmission and 180-day in-hospital mortality, and its corresponding relative importance in patients with Ischemic heart disease: a machine learning approach. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct; 21(5):1043-1048.
    View in: PubMed
    Score: 0.031
  18. Babcock A, Moussa RK, Diaby V. Prevalence and effects of suicidal ideation diagnosis code position in claims on readmission rate estimates. Res Social Adm Pharm. 2021 06; 17(6):1174-1180.
    View in: PubMed
    Score: 0.030
  19. Ding DD, Balkrishnan R, Diaby V. In our war against the opioid epidemic, could 'weed' be a winner? Expert Rev Pharmacoecon Outcomes Res. 2020 Oct; 20(5):423-429.
    View in: PubMed
    Score: 0.030
  20. Babcock A, Ali AA, Balkrishnan R, Montero A, Diaby V. Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary. J Manag Care Spec Pharm. 2020 Jul; 26(7):826-831.
    View in: PubMed
    Score: 0.030
  21. Nkemdirim Okere A, Sanogo V, Balkrishnan R, Diaby V. A quantitative analysis of the effect of continuity of care on 30-day readmission and in-hospital mortality among patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2020 Sep; 29(9):105053.
    View in: PubMed
    Score: 0.030
  22. Moussa RK, Diaby V. Self-assessed life expectancy among older adults in C?te d'Ivoire. BMC Public Health. 2020 Jun 15; 20(1):932.
    View in: PubMed
    Score: 0.030
  23. Tran PT, Diaby V. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. J Manag Care Spec Pharm. 2020 Feb; 26(2):221.
    View in: PubMed
    Score: 0.029
  24. Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang CY, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Breast. 2020 Feb; 49:141-148.
    View in: PubMed
    Score: 0.029
  25. Xiao H, Jiang X, Chen C, Wang W, Wang CY, Ali AA, Berthe A, Moussa RK, Diaby V. Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study. Res Social Adm Pharm. 2020 Aug; 16(8):1095-1099.
    View in: PubMed
    Score: 0.029
  26. Ali AA, Tawk R, Xiao H, Campbell E, Semykina A, Montero AJ, Mogos M, Diaby V. Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data. Cancer Med. 2019 01; 8(1):117-127.
    View in: PubMed
    Score: 0.027
  27. Okere AN, Ezendu K, Berthe A, Diaby V. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. J Manag Care Spec Pharm. 2018 Feb; 24(2):142-152.
    View in: PubMed
    Score: 0.025
  28. Okere AN, Montesdeoca J, Glasper A, Diaby V. An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review. Curr Diabetes Rev. 2018; 14(4):363-375.
    View in: PubMed
    Score: 0.025
  29. Diaby V, Ali AA, Williams KJ, Ezendu K, Soto-Perez-de-Celis E, Chavarri-Guerra Y, de Lima Lopes G. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast Cancer Res Treat. 2017 Dec; 166(3):951-963.
    View in: PubMed
    Score: 0.025
  30. Ali AA, Xiao H, Tawk R, Campbell E, Semykina A, Montero AJ, Diaby V. Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. Curr Med Res Opin. 2017 02; 33(2):391-400.
    View in: PubMed
    Score: 0.023
  31. Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016 11; 160(1):187-196.
    View in: PubMed
    Score: 0.023
  32. Diaby V, Ali AA, Adunlin G, Kohn CG, Montero AJ. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin. 2016 06; 32(6):991-6.
    View in: PubMed
    Score: 0.022
  33. Diaby V, Sanogo V, Moussa KR. ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare. Expert Rev Pharmacoecon Outcomes Res. 2016; 16(1):141-7.
    View in: PubMed
    Score: 0.021
  34. Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 2015 May; 151(1):27-40.
    View in: PubMed
    Score: 0.021
  35. Diaby V, Goeree R, Hoch J, Siebert U. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb; 15(1):13-9.
    View in: PubMed
    Score: 0.020
  36. Diaby V, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat. 2014 Aug; 146(3):669-73.
    View in: PubMed
    Score: 0.020
  37. Diaby V, Adunlin G, Zeichner SB, Avancha K, Lopes G, Gluck S, Montero AJ. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):433-41.
    View in: PubMed
    Score: 0.020
  38. Diaby V, Adunlin G, Montero AJ. Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88. J Med Econ. 2014 Apr; 17(4):248-9.
    View in: PubMed
    Score: 0.019
  39. Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014 Feb; 32(2):101-8.
    View in: PubMed
    Score: 0.019
  40. Diaby V, Goeree R. How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb; 14(1):81-99.
    View in: PubMed
    Score: 0.019
  41. Goeree R, Diaby V. Introduction to health economics and decision-making: Is economics relevant for the frontline clinician? Best Pract Res Clin Gastroenterol. 2013 Dec; 27(6):831-44.
    View in: PubMed
    Score: 0.019
  42. Diaby V, Lachaine J. An application of a proposed framework for formulary listing in low-income countries: the case of C?te d'Ivoire. Appl Health Econ Health Policy. 2011 Nov 01; 9(6):389-402.
    View in: PubMed
    Score: 0.016
  43. Diaby V, Di? Kakou H, Lachaine J. Eliciting preferences for reimbursed drugs selection criteria in C?te d'Ivoire. Patient. 2011; 4(2):125-31.
    View in: PubMed
    Score: 0.016
  44. Diaby V, Perreault S, Lachaine J. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. Maturitas. 2007 Oct 20; 58(2):138-49.
    View in: PubMed
    Score: 0.012
  45. Lorenzi M, Ali SN, Cadarette S, Ebohon S, Diaby V, Mathur M, Fernandes AW. Association Between Surrogate Endpoints and Clinical Outcomes in Immunoglobulin?A Nephropathy: A Systematic Literature Review. Adv Ther. 2025 Oct; 42(10):4824-4865.
    View in: PubMed
    Score: 0.011
  46. Ali SN, Fusco N, Makhija D, Diaby V, Oladapo T, Devani D, Pinto C, Mathur M, Fernandes AW. Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review. BMC Nephrol. 2025 May 19; 26(1):249.
    View in: PubMed
    Score: 0.011
  47. Winterstein AG, Ewig CLY, Wang Y, Smolinski NE, Toyserkani GA, LaCivita C, Lackey L, Eggers S, Zhou EH, Diaby V, Sarayani A, Thai T, Maro JC, Rasmussen SA. Teratogenic Risk Impact and Mitigation (TRIM): Study Protocol for the Development of a Decision Support Tool to Prioritize Medications for Risk Mitigation. Drug Saf. 2025 Feb; 48(2):107-117.
    View in: PubMed
    Score: 0.010
  48. Garg M, Venugopalan V, Vouri SM, Diaby V, Iovine NM, Wilson DL, Park H. Trends in the appropriateness of oral antibiotic prescriptions dispensed in the United States from 2010 to 2018. Pharmacotherapy. 2024 Sep; 44(9):701-710.
    View in: PubMed
    Score: 0.010
  49. Tran PT, Nduaguba SO, Wang Y, Diaby V, Finelli L, Choi Y, Winterstein AG. Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5?Years of Age in the USA. Influenza Other Respir Viruses. 2024 07; 18(7):e13347.
    View in: PubMed
    Score: 0.010
  50. Chang CY, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, Lo-Ciganic WH. Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors. Br J Cancer. 2024 Jun; 130(12):1943-1950.
    View in: PubMed
    Score: 0.010
  51. Chang CY, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, Lo-Ciganic WH. Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors. Breast Cancer Res Treat. 2024 Apr; 204(3):561-577.
    View in: PubMed
    Score: 0.010
  52. Garg M, Venugopalan V, Vouri SM, Diaby V, Iovine NM, Park H. Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population-based propensity score-matched cohort study. Pharmacotherapy. 2023 09; 43(9):883-893.
    View in: PubMed
    Score: 0.009
  53. Chang CY, Park H, Hincapie-Castillo JM, Heldermon CD, Diaby V, Yang S, Wilson DL, Lo-Ciganic WH. Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression. J Manag Care Spec Pharm. 2023 Apr; 29(4):431-445.
    View in: PubMed
    Score: 0.009
  54. Jiang X, Diaby V, Vouri SM, Lo-Ciganic W, Parker RL, Wang W, Chang SH, Wilson DL, Henry L, Park H. Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs. Am J Prev Med. 2023 01; 64(1):96-104.
    View in: PubMed
    Score: 0.009
  55. Tran PT, Nduaguba SO, Diaby V, Choi Y, Winterstein AG. RSV testing practice and positivity by patient demographics in the United States: integrated analyses of MarketScan and NREVSS databases. BMC Infect Dis. 2022 Aug 08; 22(1):681.
    View in: PubMed
    Score: 0.009
  56. Abegaz TM, Diaby V, Sherbeny F, Ali AA. Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA. Clin Drug Investig. 2022 Jun; 42(6):501-511.
    View in: PubMed
    Score: 0.009
  57. Jiang X, Vouri SM, Diaby V, Lo-Ciganic W, Parker R, Park H. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C. J Manag Care Spec Pharm. 2021 Oct; 27(10):1388-1402.
    View in: PubMed
    Score: 0.008
  58. van Boemmel-Wegmann S, Brown JD, Diaby V, Huo J, Silver N, Park H. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. JCO Oncol Pract. 2022 01; 18(1):e163-e174.
    View in: PubMed
    Score: 0.008
  59. Jiang X, Parker RL, Vouri SM, Lo-Ciganic W, Diaby V, Henry L, Park H. Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders. Am J Prev Med. 2021 10; 61(4):576-584.
    View in: PubMed
    Score: 0.008
  60. Alsuhibani A, Albogami Y, Diaby V, Friedman J, Vouri SM. Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study. Surg Obes Relat Dis. 2021 May; 17(5):939-946.
    View in: PubMed
    Score: 0.008
  61. Huo J, Hong YR, Turner K, Diaby V, Chen C, Bian J, Grewal R, Wilkie DJ. Timing, Costs, and Survival Outcome of Specialty Palliative Care in Medicare Beneficiaries With Metastatic Non-Small-Cell Lung Cancer. JCO Oncol Pract. 2020 12; 16(12):e1532-e1542.
    View in: PubMed
    Score: 0.008
  62. Tran AD, Fogarty G, Nowak AK, Diaby V, Hong A, Watts C, Morton RL. Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases. Appl Health Econ Health Policy. 2020 10; 18(5):679-687.
    View in: PubMed
    Score: 0.008
  63. Wang CY, Pham PN, Kim S, Lingineni K, Schmidt S, Diaby V, Brown J. Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States. Clin Transl Sci. 2020 03; 13(2):352-361.
    View in: PubMed
    Score: 0.007
  64. Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020 10; 20(5):724-735.
    View in: PubMed
    Score: 0.007
  65. Baltussen R, Marsh K, Thokala P, Diaby V, Castro H, Cleemput I, Garau M, Iskrov G, Olyaeemanesh A, Mirelman A, Mobinizadeh M, Morton A, Tringali M, van Til J, Valentim J, Wagner M, Youngkong S, Zah V, Toll A, Jansen M, Bijlmakers L, Oortwijn W, Broekhuizen H. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. Value Health. 2019 11; 22(11):1283-1288.
    View in: PubMed
    Score: 0.007
  66. Shah CH, Balkrishnan R, Diaby V, Xiao H. Examining factors associated with adherence to hormonal therapy in breast cancer patients. Res Social Adm Pharm. 2020 04; 16(4):574-582.
    View in: PubMed
    Score: 0.007
  67. Boulin M, Diaby V, Tannenbaum C. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada. PLoS One. 2016; 11(9):e0162951.
    View in: PubMed
    Score: 0.006
  68. Tannenbaum C, Diaby V, Singh D, Perreault S, Luc M, Vasiliadis HM. Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. Drugs Aging. 2015 Apr; 32(4):305-14.
    View in: PubMed
    Score: 0.005
  69. Adunlin G, Diaby V, Xiao H. Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis. Health Expect. 2015 Dec; 18(6):1894-905.
    View in: PubMed
    Score: 0.005
  70. Adunlin G, Diaby V, Montero AJ, Xiao H. Multicriteria decision analysis in oncology. Health Expect. 2015 Dec; 18(6):1812-26.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support